Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
IMVT heads into its November 6 earnings with short interest building steadily, the stock down 18% over the past month, and a wide gap between where bulls think it can go and where it trades today.
The short side tells a consistent, if not dramatic, story. Short interest has climbed to 10% of the free float, up roughly 4.5% over the week and 7% over the past month, a steady accumulation rather than a sudden spike. At 17.6 million shares short, this is real conviction from bears, not noise. The borrow market, though, offers little friction to new shorts: availability is running at 769%, meaning for every share already borrowed, roughly 7.7 more are sitting idle in the lending pool. Cost to borrow is just 0.45%, close to the floor. There is no squeeze pressure here. The ORTEX short score holds at 67.6, broadly stable over the past two weeks, confirming this as a well-established bear position rather than an accelerating one.
Options positioning is calmer than the short interest picture might suggest. The put/call ratio is 0.34, modestly above its 20-day average of 0.30 but less than one standard deviation from the mean. Against a 52-week low of 0.05 and a high of 0.47, the reading sits in the middle of its range. Options traders are not adding to the bearish case in any meaningful way this week.
The analyst community paints a genuinely split picture. The consensus rating is hold, anchored by four hold ratings, but most of the price target activity since May has been bullish. JP Morgan raised its target to $50 in early August while keeping its overweight rating. Citi and Guggenheim both carry buy ratings with targets well above $60 and $62 respectively. Against a current price of $32, those targets imply significant upside, but Goldman Sachs sits at neutral with a $32 target, essentially where the stock trades. B of A's buy target of $43 and Truist's hold target of $30 bracket the current price closely. The spread is wider than usual for a stock of this size, reflecting genuine disagreement about whether IMVT-1402's Phase 2 pipeline can clear its remaining clinical and regulatory hurdles without delays. All analyst data cited here is from May to August 2026.
The ownership picture adds important context. Roivant Sciences holds nearly 55% of shares, making it effectively a controlled company. Its 13D filing on record designates it as an activist holder in the SEC sense, though at this scale the position is more strategic than agitator. FMR and BlackRock have both added shares recently, with BlackRock adding around 606,000 shares as of September 30 and T. Rowe Price adding 533,000 over the same period. Those are incremental additions, not transformational, but they point to some institutional conviction at these lower prices. Farallon Capital built a position of 5.8 million shares as of June 30, up from near zero, which is the most significant pure-money-manager addition in the recent holder data. On the insider side, CEO Eric Venker exercised options on October 1 and immediately sold the resulting shares at around $33.65 for proceeds of roughly $2.9 million. This is a common exercise-and-sell pattern and carries less signal than a discretionary open-market purchase. The 90-day net insider position is a modest net negative at roughly $1.1 million sold.
Wikipedia attention for IMVT has spiked to a z-score of 5.2 against its own 90-day history, according to ORTEX Alt Data, suggesting a recent burst of retail interest. That is an attention signal, not a revenue or clinical indicator, but it is worth noting in the context of a stock down 18% in a month with a headline clinical catalyst approaching in four weeks.
The stock's three most recent earnings reactions were muted: a 2% decline on the day in September 2026 and small positive moves in August. With the next print on November 6 and the clinical narrative still open, what to watch is whether short interest continues to drift higher into that date or whether any resolution on the Phase 2 data timeline shifts the balance between those $30 hold targets and $60-plus buy cases.
See the live data behind this article on ORTEX.
Open IMVT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
